Commitments and Contingencies (Details) - USD ($)				3 Months Ended		9 Months Ended
	Jul. 01, 2021	Mar. 28, 2021	Aug. 25, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Oct. 09, 2020
Commitments and Contingencies [Line Items]
Rent expense				$ 9,162	$ 14,174	$ 64,555	$ 32,076
Percentage of company's annual requirements			100.00%
Allowance for doubtful accounts								$ 257,463
Accrued settlement expense								39,486,139
Additional settlement liability						21,365,641
Proceeds from issuance of common stock for exercise of warrant						16,699,489
Prepaid expenses and other current assets				6,350,889		6,350,889		$ 240,352
GEM Warrant [Member]
Commitments and Contingencies [Line Items]
Warrant issued		3,329,812
Exercise price of warrant		$ 3.19
Warrants to purchase shares		1,496,216
Warrants to purchase shares, amount		$ 7,500,018
Warrants expire period		The GEM Warrant were valid for a period of three years from the date NeuroRx’s stock is listed for trading on a national securities exchange or consummation of a reverse merger transaction of the type contemplated by the Merger Agreement.
Reimbursements from Relief Therapeutics Holding AG
Commitments and Contingencies [Line Items]
Reimbursable expenses						13,800,000
Payment to related party						$ 10,900,000
Phase II Inhaled clinical trial of Aviptadil
Commitments and Contingencies [Line Items]
Research commitments	$ 7,400,000
GEM Share Subscription Facility Agreement
Commitments and Contingencies [Line Items]
Share subscription agreement term						3 years
Share subscription value				95,600,000		$ 95,600,000
Commitment fee						1,900,000
Polypeptide [Member]
Commitments and Contingencies [Line Items]
Purchase commitments									$ 5,255,000
Prepaid expenses and other current assets				1,407,500		1,407,500
Sponsored Research Agreement [Member]
Commitments and Contingencies [Line Items]
Research commitments						399,320
Research commitments paid				$ 90,112		$ 216,269